` VIRP (Virbac SA) vs DAX Index Comparison - Alpha Spread

VIRP
vs
DAX Index

Over the past 12 months, VIRP has underperformed DAX Index, delivering a return of -12% compared to the DAX Index's 22% growth.

Stocks Performance
VIRP vs DAX Index

Loading

Performance Gap
VIRP vs DAX Index

Loading
VIRP
DAX Index
Difference

Performance By Year
VIRP vs DAX Index

Loading
VIRP
DAX Index
Add Stock

Competitors Performance
Virbac SA vs Peers

DAX Index
VIRP
LLY
JNJ
NOVO B
ROG
Add Stock

Virbac SA
Glance View

Economic Moat
None
Market Cap
2.6B EUR
Industry
Pharmaceuticals

Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

VIRP Intrinsic Value
362.74 EUR
Undervaluation 16%
Intrinsic Value
Price
Back to Top